Legato Merger Corp III: Legato Merger Corp. III Announces Receipt of Audit Opinion with Going Concern Explanation

Legato Merger Corp. III (NYSE American: LEGT U, LEGT, LEGT WS) (the "Company") announced that, as previously disclosed in its Annual Report on Form 10-K for ...

Oxbridge Re Holdings Limited: Oxbridge Highlights Strong 2025-26 Performance, Platform Expansion, and Market Opportunity; Reports Q4 and Full-Year Results

Oxbridge Re Holdings Limited (NASDAQ: OXBR,, (the "Company"), a leader in digitizing reinsurance securities as tokenized real-world assets ...

AirJoule Technologies Corporation: AirJoule Technologies Announces Fourth Quarter and Full Year 2025 Results and Provides Business Update

AIRJ Achieves 2025 Objectives Across Technology Validation, Product Development, and Strategic Partnerships RONAN, Mont., March 30, 2026 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: ...

BTQ Technologies Corp.: BTQ Technologies Provides Full-Year 2025 Corporate Update Highlighting Commercial Progress Across QCIM, QPerfect, QSSN and Bitcoin Quantum

VANCOUVER, BC, March 30, 2026 /PRNewswire/ - BTQ Technologies Corp. ("BTQ" or the "Company") (Nasdaq: BTQ) (CBOE CA: BTQ), a global quantum technology company focused ...

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody ...

Future Money Acquisition Corporation Announces Completion of $112,000,000 Initial Public Offering, Including Partial Exercise of Overallotment Option

Future Money Acquisition Corporation (NASDAQ: FMACU) (the "Company") today announced the closing of its initial public offering of 11,200,000 units at ...

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...

Aktis Oncology Inc.: Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical tr ...

Palisade Bio, Inc.: Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat populationPhase 1b data demonstrate endoscopic improvement ...

GlucoTrack, Inc.: Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued paten ...

BridgeBio Pharma, Inc.: Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54

Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era ...

Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of ...